Melbourne Genomics Health Alliance
System Design Specification
Supplier Briefing
Information Management Product Shortlisting (EOI)
Contents
01
Melbourne Genomics Health Alliance (The Alliance)
02
Our targeted architecture and scope
03
Competitive dialogue and RFP
04
What we require from you
05
Key information
06
Probity and disclaimer
Melbourne Genomics Health Alliance | Supplementary Information Material
2
Melbourne Genomics Health Alliance
(The Alliance)
01
‘Most health systems
around the world are not fit
to shepherd genome
sciences into routine health
care.’
Geoffrey Ginsburg
Director
Center for Applied Genomics and Precision Medicine, Duke University
Comment in Nature, 2014
Barriers to Implementation
Lack of evidence for the value of genomics
Limited access to testing
Concerns about ethical issues
Poor pathway from research to clinical care
Lack of integration into healthcare system
Melbourne Genomics Health Alliance | Supplementary Information Material
5
The Melbourne Genomics Is An Alliance of 10 Leading
Healthcare, Diagnostic and Research Organisations
The Melbourne Genomics Health Alliance is an alliance of ten leading healthcare and research organisations dedicated to
bringing the global knowledge of genomics to benefit the individual care of Victorians.
Genomics medicine holds huge promise for human health, but, across the world, experience shows that there are many
challenges to implementing genomics into healthcare.
These challenges include:
•
Upskilling existing healthcare professionals and fostering the new professions needed;
•
Knowing which patients will benefit from genomics;
•
Managing the ‘big data’ generated by genomics sequencing; and
•
Harnessing the latest genome research so it can benefit patients sooner.
The 10 Alliance members recognise that to create lasting change and maximum patient benefit, organisations need to work
together. The Alliance is moving into an exciting phase, with key programs of work to be delivered throughout 2016-2019.
The Alliance’s work is assessing genomics in practice, establishing the best systems, harnessing the latest research,
upskilling health workers and ensuring appropriate access to quality information.
This alliance of Victoria’s healthcare and medical research strengths, supported by government, is uniquely placed to
develop the enormous potential of genomics to improve the health of Victorians.
Melbourne Genomics Health Alliance | Supplementary Information Material
6
The Melbourne Genomics Health Alliance
Melbourne Genomics Health Alliance | Supplementary Information Material
7
The Journey to Implementation
Discovery
Research
Translational
Research
Implementation
Routine Practice
Research Institutes and
Universities
Australian Genomics
Health Alliance
Melbourne Genomics
Health Alliance
Clinical Genetics
Services and Hospitals
Melbourne Genomics Health Alliance | Supplementary Information Material
8
Melbourne Genomics’ has Four Core Objectives
Genomics is of real benefit to Victorians
There is evidence to support good practice in genomics medicine in Victoria, and sequencing results are
of demonstrated use to patients and clinicians. Patients are engaged with genomics, and understand
the implications of a genomics test.
Excellence in genomics
Victorian healthcare workers are confident in the use of genomics in patient care, and diagnostic
laboratories
are
applying
state-of-the-art
genomics
analysis.
A proactive and learning culture ensures the latest approaches in genomics medicine are able to be
rapidly adopted and evaluated.
A shared system
There is one single approach in Victoria, with common standards, policies and procedures and a secure,
shared system for the management and use of genomics information.
Victoria is the place for genomics in healthcare
Alliance members and the State of Victoria are recognised nationally and internationally as leaders in
the application of genomics in healthcare.
Melbourne Genomics Health Alliance | Supplementary Information Material
9
Multidisciplinary Collaboration
Health informaticians Communication/media professionals
Health economists
Patients
CEOs/leaders
Lawyers Data curators
Data scientists Healthcare administrators
Neurologists Parents/carers
Software engineers
Laboratory scientists
Clinicians Metabolic physicians
Genetic counsellors
Information technology experts
Haematologists Medical researchers
Pathologists
Business Development Clinical geneticists
Ethicists
Paediatricians Epileptologists Gastroenterologists
Oncologists
Melbourne Genomics Health Alliance | Supplementary Information Material
Community members
10
One Test – Lifetime Analysis by Indication
Clinical Care
Management
Re-analysis
Research
Prevention
Melbourne Genomics Health Alliance | Supplementary Information Material
11
State-wide Approach
Alliance
Members’
clinical
systems
Members’
pathology
systems
Genomics
clinical data
platform
External
systems
Research
Melbourne Genomics Health Alliance | Supplementary Information Material
12
Streams of Work
Workforce development
Assessing the value
of genomics
Innovation and rapid adoption
Genomics information
– access & analysis
National and international impact
Disease Flagships
Melbourne Genomics Health Alliance | Supplementary Information Material
13
Melbourne Genomics’ Current Areas of Work (2016-2019)
Provide genomics sequencing to patients
Around 2,000 genomics sequencing tests will be provided to Victorians via the Disease Flagships: multi-disciplinary teams of clinicians,
researchers and medical scientists from organisations across the Alliance. Flagships simultaneously provide sequencing to patients and
develop evidence for genomics, while upskilling the workforce and testing systems and approaches in real-world settings.
Foster adoption of genomics
The Alliance will foster a healthcare culture that supports efficient and effective use of genomics information. The Alliance is building the
literacy, skills and confidence of clinical and diagnostic professionals, and developing mechanisms to grow the informatics and
evaluation workforces needed to support genomics in practice. This work will result in a cohort of leaders in genomics medicine who can
be champions of change, as well as a wider interested group of professionals across the Victorian healthcare system.
Build evidence for genomics
Evaluating the best use of genomics in healthcare is vital. The Alliance’s work will demonstrate which patients will benefit and how, as
well as identifying how clinicians can best be supported to provide testing to the right patient, at the right time.
Develop a single, shared approach to genomics information
To underpin the effective use of genomics in healthcare, the Alliance is developing coordinated standards, policies, processes and
systems for the management and use of genomics information. This work will enable:
•
•
Secure, ethical and timely access to genomics information for clinicians, patients and researchers; and
Integration with hospitals.
Melbourne Genomics Health Alliance | Supplementary Information Material
14
Information management (IM) program
02
Our Journey Towards Product Shortlisting
Dec 2014
2015
July 2015
Information
Management
Requirements
Melbourne
Genomics
Health
Alliance
Business
Plan
Solution
Architecture
Melbourne Genomics Health Alliance | Supplementary Information Material
Feb 2016
Data
Governance
Framework
July 2016
May 2016
Status
Assessment
- Business
Process and
IT System
Information
Management
Target State
Scenarios &
Program
Definition
Business,
Information
and NonFunctional
Requirements
Information
Management
Delivery Plan
(Horizon1)
16
The Alliance Has Established A Set of Guiding Principles
That Will Inform The Desired End State
Business Principles
Technology Principles
Assessing genomics
The Alliance leads the way in investigating how
genomics sequencing can best benefit patients.
Working together
The Alliance understands that to create lasting
change and maximum patient benefit,
organisations
need
to
work
together
harnessing expertise from the best clinicians,
researchers and experts in the field.
Providing the right information
A secure system for genomics information will
be developed in Victoria that supports doctors,
researchers and patients to access the right
information when they need it.
Melbourne Genomics Health Alliance | Supplementary Information Material
17
IM Solution - Policy & Process, People and Technology
Melbourne Genomics Health Alliance | Supplementary Information Material
18
The IM Solution Horizons (Technology)
High Level Architecture
Horizon 1 (in-scope)
Melbourne Genomics Health Alliance | Supplementary Information Material
Lay the foundation and connect the pipes for early adoption
Horizon 2
Enabling digital channels and enhanced data
Horizon 3
Decision support capability and fully integrated platform
19
High Level Architecture
The Scope for this EOI (Horizon 1)
Core Components for Horizon 1
Genomics Repository (ability to store & manage data):
•
Including an OMICS data model; and
•
Including a Phenotype data model.
Component Architecture
Diagnostic Tools
Analysis Platform (ability to run a computational pipeline):
•
9
Visual platform to control the deployment of multiple pipelines
(containerised).
Curation Platform (ability to curate variants):
•
Melbourne Genomics Health Alliance | Supplementary Information Material
Visual platform to enable curation and reporting of genomics tests.
20
The Alliance’s Vision For Technology, Based On
Components to Enable Genomics Within Clinical Practice
Integrated Genomics: Core
platform systems required to
deliver the solution;
1. Test management system;
2. Content management
system;
3. Clinical decision support
system;
4. Learning management
system;
5. Issue management
system;
6. Change management
system;
7. Financial management
system; and
8. Operational Reporting.
Alliance Members (systematic access):
Capabilities required from member
organisations.
Platform Services: Core
platform services offered
across the solution.
Melbourne Genomics Health Alliance | Supplementary Information Material
Access Channels (human access): People within the Alliance
will access the platform through information presented within
portals.
Integration: Enabling
orchestration of requests
within the platform from
external systems.
Diagnostic Pipeline:
Components enabling
the automated pipeline.
Analytics: Component
enabling the creation of
models for research across
data available within the
platform (and aggregated
data which is linked)
Platform Data: The platform will store and make
available information required for genomics testing
and aggregated information for research.
21
The Logical Blueprint Represents the New Way the Alliance
Will Work and the Capabilities Required
Melbourne Genomics Health Alliance | Supplementary Information Material
22
Product shortlisting process
03
Product Shortlisting Presents An Opportunity For You to
Showcase Product(s) In-scope For Horizon 1
What is Product Shortlisting (Competitive Dialogue)?
This model is a fast tracked approach that involves the Alliance and
shortlisted suppliers to work closely and collaboratively via structured
workshops, exploring the proposed solution and business requirements
with the clear objective to refine and bring to life the best solution for the
Alliance.
Why product shortlisting?
This model presents the Alliance with the opportunity to interact and build
relationships with suppliers dissecting our proposed solution, enabling our
team and key stakeholders to participate in designing a solution that is
innovative and is fit-for-purpose to the Alliance’s future requirements.
How will product shortlisting be executed?
Stage
Stage
Stage
1
2
3
Pre-Qualification (EOI);
Pre-Qualification and Open Dialogue for Horizon 1
Product Shortlisting
1
Pre-Qualification
(EOI)
2
Open Dialogue
3
Limited RFP
Future
Engagement
Supplier briefing & release
of EOI information pack
Supplier response
submission
Short-listed supplier
workshops
Alliance evaluation of
supplier submission
Alliance evaluation of
supplier and refined
solution
Limited RFP & Alliance
selection of product
/system integrators &
contracting
Invitation to short listed
suppliers to participate in
open dialogue
Open Dialogue; and
Limited RFP.
Melbourne Genomics Health Alliance | Supplementary Information Material
Aug 2016
Sep-Nov 2016
Dec 2016 - Onwards
24
Product Shortlist Focus Activities
The pre-qualification and open dialogue stages represent the best opportunity for suppliers to showcase their
capabilities and overall fit with the Alliance’s strategic vision.
In Scope
Future
Engagement
Product Suppliers
The pre-qualification (EOI) and open dialogue stages are limited to product
suppliers only. Suppliers must participate and comply with the Alliance’s
requirements in the pre-qualification (EOI) to be eligible to progress to the open
dialogue stage.
The Alliance will consider services such as project management and
implementation as part of the limited RFP process later this year. This may
provide an opportunity for Systems Integrators/Prime Vendors/Implementation
Partners to submit a proposal partnering with one of the shortlisted product
suppliers.
Melbourne Genomics Health Alliance | Supplementary Information Material
25
Key Phases and Anticipated Timeframes For Product Shortlist
PreQualification
(EOI)
Alliance evaluation
and suppliers
shortlist completed
August 31st 2016
Open
Dialogue
Q&A Closed
August 16th 2016
Workshop #1
Product
Discovery
September 14th15th 2016
Limited RFP
Issued
December 2016
Workshop #3
Implementation &
Operations
October 5th-6th
2016
2
1
EOI Briefing
Session and Info
Pack Released
August 9th 2016
EOI Supplier
Response Due
August 22nd
2016
Product invitation
to participate in
Open Dialogue
September 1st
2016
Limited
RFP
3
Workshop #2
Solution Deep Dive
September 20th-21st
2016
Alliance evaluation
and supplier
assessment
completed
October 2016
Dates may be subject to change
Melbourne Genomics Health Alliance | Supplementary Information Material
26
What we require from you
04
What You Will Receive From Us, What We Expect From You
and Expected Outcomes
1 Pre-Qualification (EOI)
2 Open Dialogue
3
Limited RFP
What you will receive:
What you will receive:
What you will receive:
• Supplier Briefing;
• Open Dialogue Information Pack;
• Vendor briefing;
• Attachment for Response
• Detailed Alliance System Design Specification
documentation (Solution Architecture);
• RFP Information Pack (including product list);
• Functional & non-functional requirements; and
• Q&A Period.
• Supplementary Information Material (EOI); and
• Q&A Period.
• Response template; and
• Scenarios.
What we expect from you:
What we expect from you:
What we expect from you:
• Limited to product (suppliers);
• Limited to product (suppliers);
• RFP open to System Integrators and suppliers (product);
• Alliance EOI IM Horizon 1 Product Options Response; and
• Participation in three scheduled workshops;
• Compliance with procurement guidelines.
• Presentation & demonstrations (+ supporting material); and
• Presentation, demonstrations as required and site visits
(supporting material to be provided); and
• Compliance with procurement guidelines (NDA required to
be signed).
• Compliance with procurement guidelines (NDA required to
be signed).
Outcome Expected:
Outcome Expected:
Outcome Expected
• Suppliers notified of evaluation outcomes; and
• Suppliers notified of evaluation outcomes; and
• The Alliance selects preferred vendor(s); and
• Shortlisted suppliers invited to participate in Open Dialogue.
• Endorsement to proceed with limited RFP.
• Procurement and contract execution.
Melbourne Genomics Health Alliance | Supplementary Information Material
Details may be subject to change
28
It’s Critical Suppliers Responding to the EOI Provide a
Response to the Questions Outlined in this Section
Supplier Response Information
• Word or PDF format (10mb)
• Email submission
• All questions must be answered
• No appendices
• Product Suppliers can respond to all 3 solution components
(genomic repository, analysis platform and curation platform)
Organisation & Experience
Q1
Please provide a brief overview of your organisation (point of contact details, size, number of employees, revenue, local
and/or global presence and support capability as relevant) and which functional areas you are responding to.
300 word limit
Q2
If your product(s) are successfully short-listed and invited to the open dialogue stage, please indicate if you will be available to
participate in the 3 workshops, with at least one member of your team on-site for workshops 1 and 2
yes / no
Q3
If your product(s) are successfully short-listed and invited to participate in the open dialogue workshops, are you able to
create a demonstration environment for our evaluation team to become familiar with your product(s)?
yes / no
Q4
Q5
Q6
Please indicate if your product(s) are currently deployed for use in a clinical Genomics Medicine setting.
Please indicate the number of instances your organisation’s product(s) has been implemented in a production environment
and provide examples of relevant clients/sites, including one operating an Alliance/federated model. (max 5 sites)
Please describe the key benefits/outcomes achieved by the site(s) listed in question 5 beyond the successful product delivery.
Melbourne Genomics Health Alliance | Supplementary Information Material
yes / no
1 page limit
per client
29
It’s Critical Suppliers Responding to the EOI Provide a
Response to the Questions Outlined in this Section
Per Product
Q7
Please provide a brief overview of proposed product(s) outlining how each product(s) may fit the business and technology
vision within the Alliance.
1 page limit per
product
Q8
For each product proposed, please outline the roadmap (1yr-5yr)
1 page limit per
product
Q9
For each product proposed, please list current standards which are adhered to i.e. Interoperability for integration (e.g. PAS,
LIMS, EMR etc.) or defined data models.
1 page limit
Q10
For each product proposed, please indicate how this product can be hosted (locally instance, cloud based or hybrid) offering
details on options.
1 page limit
Per Technology
Q11 For each of the product(s) proposed, please outline how portable (modular) the product architecture is i.e. decoupled.
1 page limit
Q12 For each of the product(s) proposed, please outline how extendable the product is i.e. options for custom development.
1 page limit
Q13
For each of the product(s) proposed, please outline the level of configuration available within the standard product.
Q14 For each of the product(s) proposed, please outline how scalable the product(s) are i.e. size of deployment, volume of
transactions, number of users.
Melbourne Genomics Health Alliance | Supplementary Information Material
1 page limit
1 page limit
30
It’s Critical Suppliers Responding to the EOI Provide a
Response to the Questions Outlined in this Section
Per Technology (continued)
Q15 For each of the product(s) proposed, please outline current security, identity and access standards which underpin
the design.
Q16
For each of the products(s) proposed, outline any open source libraries or projects which have been leveraged.
1 page limit
1 page limit
Fit with the Alliance
Q17
Provide details of your organisational culture and how you partner with clients/sites to deliver successful projects
and adoption. Please include relevant examples.
300 word limit
Q18
Please provide details of your user groups and communities, corporate values, corporate responsibility and
participation within communities (local and global if applicable).
300 word limit
Melbourne Genomics Health Alliance | Supplementary Information Material
31
What We Require From You During the Pre-qualification (EOI)
Supplier Briefing Session
The supplier briefing will be held at 8am (AEST), Tuesday the 9th August 2016 at the Walter and
Eliza Hall Institute (WEHI), teleconferencing will be available.
Supplementary Information
Material (EOI)
The Supplementary Information Material (EOI) will be sent electronically to the nominated
supplier point of contact following the supplier briefing session.
Q&A Period
The Alliance will be using a Supplier Q&A log during the EOI period. All enquires and questions
should be sent to [email protected]. The deadline for enquires and
questions is 5pm (AEST), 16th August 2016
Supplier EOI Product
Shortlisting Response
Supplier submission must adhere to the requirements detailed in the Supplementary Information
Material. The response should answer all questions and adhere to page length and word count
guidelines (appendices will not be considered). Responses due 2pm (AEST), 22nd August 2016.
Supplier EOI Response
Evaluation
Supplier responses will be evaluated by an Alliance Evaluation Panel using agreed evaluation
criteria. Evaluation will be finalised by the Alliance by 31st August 2016.
Open Dialogue Invitation
Notification
Suppliers who have been successfully short-listed for the Open Dialogue stage will be notified by
the 1st September 2016. Details of the requirements of the Open Dialogue stage will be provided
to suppliers once acceptance to participate in the Open Dialogue has been received.
Dates may be subject to change
Melbourne Genomics Health Alliance | Supplementary Information Material
32
Key information
05
Communication and Enquiries for Product Shortlisting Will Be
Managed by a Dedicated Team Member of the Alliance
General Information
The closing for the enquires is;
•
5pm (AEST), Tuesday the 16th August 2016.
We ask that all enquires are directed through the Alliance procurement team. All
enquiries, will be documented with written responses to be communicated to all
registered suppliers electronically. Please allow for 24-48hrs for responses to be
published.
[email protected]
(using the subject title: Product Shortlisting enquiries)
Contact Details
Todd Jasper
5pm (AEST)
16th of August
2016
Melbourne
Genomics
Health
Alliance
Important Information
The Alliance reserves the right to only release information that is deemed relevant
for the different stages of the product shortlisting process.
enquiries@
melbournegenomics.org.au
Please do not contact anyone else from within the Alliance or Alliance members
regarding this product shortlist process.
Failure to comply with these instructions and requirements may result in your
participation being withdrawn.
Melbourne Genomics Health Alliance | Supplementary Information Material
34
Product Suppliers are Required to Submit Responses in
Accordance with the Instructions Described on this Page
General Information
The closing for the EOI submission is;
•
2pm (AEST), Monday the 22nd of August, 2016.
One electronic copy PDF or word format (10mb) of your submission, the response
should answer all questions and adhere to page length and word count guidelines
(appendices will not be considered). Please email response to the following;
[email protected]
using the subject title: Product Shortlisting EOI Submission
Important Information
The pre-qualification (EOI) and open dialogue stages are limited to product
suppliers only. Suppliers must participate and comply with the Alliance’s
requirements in the pre-qualification (EOI) to be eligible to progress to the open
dialogue stage.
Submission Details
Todd Jasper
2pm (AEST)
22nd, August
2016
Melbourne
Genomics
Health
Alliance
enquiries@
melbournegenomics.org.au
The Alliance will consider services such as project management and
implementation as part of the RFP process later this year. This may provide an
opportunity for Systems Integrators/Prime Vendors/Implementation Partners to
submit a proposal partnering with one of the shortlisted product suppliers.
Melbourne Genomics Health Alliance | Supplementary Information Material
35
FAQs
What is the due date of the EOI submission?
Supplier submission must adhere to the requirements detailed in the Supplementary Information Material. The
response should answer all questions and adhere to page length and word count guidelines (appendices will not
be considered). Responses due 2pm (AEST), 22nd August 2016.
How will the Supplementary Information Material be
distributed?
The Supplementary Information Material (EOI) will be sent electronically to the nominated supplier point of contact
following the supplier briefing session.
Will the Alliance distribute any additional material
for the EOI phase i.e. Requirements?
The Alliance reserves the right to only release information that is deemed relevant for the different stages of the
product shortlisting process. The Alliance does anticipate any additional material will be released for the EOI. All
product suppliers will be notified if additional material is to be released.
Can product suppliers respond with more than one
product?
Yes.
Will late EOI submissions be accepted?
No.
Where can I access the supplier Briefing Material?
http://www.melbournegenomics.org.au/expression-interest
Are you considering project management and
implementation services as part of the EOI?
No, at this stage we are looking for product functionality. Project services (from the product suppliers or partnering
with system integrators/prime suppliers) will be considered in detail as part of the RFP process.
Are product suppliers required to respond
addressing all 3 components of the solution?
No. Product suppliers may respond addressing either; one, two or all three of the core component products.
Melbourne Genomics Health Alliance | Supplementary Information Material
36
Probity and disclaimer
06
Essential Probity Elements
• All Respondents must have an equal chance of success;
• Comply with Alliance procurement rules and legislation;
• Open and transparent process;
• Accountability;
• Security and confidentiality;
• Deliver value for money; and
• Defensible.
Key Assumption: Appropriate Ethical Behaviour
Melbourne Genomics Health Alliance | Supplementary Information Material
38
Probity Process
• Probity Plan developed for the procurement;
• Commitment to transparency, equity and accountability in selection process;
• All expression of interest documentation made available in an equitable manner to all potential respondents;
• Project team briefed on their probity responsibilities. All project staff and advisors have completed:
•
Conflict of interest declarations; and
•
Confidentiality Undertakings.
• Evaluation Plan completed before your responses received.
Melbourne Genomics Health Alliance | Supplementary Information Material
39
Probity Expectation of Product Suppliers
• No approaches to staff connected with Melbourne Genomics or its advisors for assistance with bid
preparation;
• No attempts to gain preferential access to decision makers;
• Any contacts with the Alliance in relation to the procurement is through the dedicated contact points;
• No comments or lobbying in relation to the procurement; and
• Continuing disclosure of conflicts or other material matters.
Melbourne Genomics Health Alliance | Supplementary Information Material
40
Disclaimer & Confidentiality Statement
IMPORTANT NOTE:
This briefing material is the proprietary and exclusive property of Melbourne Genomics Health Alliance.
Recipients of this briefing material may only reproduce, store, transmit or use this document (whether
wholly or in part) for the purposes of responding to the product shortlisting process.
The information contained in this briefing material may be amended or varied by Melbourne Genomics
Health Alliance at its discretion. In circumstances where Melbourne Genomics Health Alliance decides to
amend or vary the information in this briefing material, then the suppliers will be notified of any such
amendment or variation in due course via preferred communication channels.
This briefing material is confidential and may contain information that is commercially sensitive. As a
condition of agreeing to participate in this product shortlisting process, suppliers must not disclose the
information contained in this briefing material to any third party, unless such disclosure is approved by
Melbourne Genomics Health Alliance.
Melbourne Genomics Health Alliance | Supplementary Information Material
41